Related Experiment Video
Updated: Jun 28, 2026
A Protocol to Evaluate and Quantify Retinal Pigmented Epithelium Pathologies in Mouse Models of Age-Related Macular Degeneration
Published on: March 10, 2023
Computerized model of cost-utility analysis for treatment of age-related macular degeneration
E C Fletcher1, R J Lade, T Adewoyin
1King's College Hospital, London, United Kingdom. emily_cfletcher@yahoo.co.uk
Purpose:
To present a computerized model assessing individualized cost utility for current treatments for neovascular age-related macular degeneration (AMD) to enhance discussion regarding treatment options.
Design:
Case- and eye-specific cost-utility analysis using individual case scenarios.
Participants:
Visual acuity data from published randomized controlled trials are incorporated into this analysis.
Methods:
Computerized model (Microsoft Visual Basic 6.0 programming) to establish preference-based cost-utility analysis in association with individual cost of treatment and blindness for neovascular AMD for both the better and worst seeing eye, with extrapolation of results over a 5-year term.
Main Outcome Measures:
Cost per quality-adjusted life-year (QALY) and cost per QALY gained for comparison of treatments for specific visual acuities.
Results:
All treatments show an increase in utility in comparison with best supportive care (BSC) if the better-seeing eye is treated. Ranibizumab, using the Phase IIIb, Multicenter, Randomized, Double-Masked, Sham Injection-Controlled Study of the Efficacy and Safety of Ranibizumab in Subjects with Subfoveal Choroidal Neovascularisation (CNV) with or without Classic CNV Secondary to AMD (PIER) regimen, is the most cost effective at $626 938 per QALY gained for treatment of the better seeing eye. To increase utility value when treating the worst seeing eye, the vision must improve to such a degree that it becomes the better seeing eye. This level of improvement is only possible if there is <9 letters difference between the 2 eyes and treated with ranibizumab. Over 5 years, increasing influence from the cost of blindness results in increasing costs for those treatments unable to stabilize vision. Within 5 years, the cost per QALY for the BSC is greater than all treatments except monthly ranibizumab injections.
Conclusions:
Assessment of cost of treatment incorporates both effectiveness of treatment, cost of treatment, and cost of blindness. Cost analysis enables incorporation of these aspects of treatment with the quality of life data to provide a better comparison of treatments over time. This analysis has provided a method for individual analysis and therefore can provide the structure for resource allocation.
Financial Disclosure(S):
The authors have no proprietary or commercial interest in any materials discussed in this article.
